company background image
HXL logo

Hexima ASX:HXL Stock Report

Last Price

AU$0.01

Market Cap

AU$1.7m

7D

-9.1%

1Y

-58.3%

Updated

15 Jul, 2024

Data

Company Financials

HXL Stock Overview

A biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia.

HXL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Hexima Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hexima
Historical stock prices
Current Share PriceAU$0.01
52 Week HighAU$0.024
52 Week LowAU$0.008
Beta0.61
11 Month Change0%
3 Month Change-16.67%
1 Year Change-58.33%
33 Year Change-94.59%
5 Year Changen/a
Change since IPO-94.87%

Recent News & Updates

Recent updates

Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Mar 21
Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Sep 06
Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Read This Before Selling Hexima Limited (ASX:HXL) Shares

Mar 02
Read This Before Selling Hexima Limited (ASX:HXL) Shares

Shareholder Returns

HXLAU BiotechsAU Market
7D-9.1%2.6%1.7%
1Y-58.3%17.9%9.2%

Return vs Industry: HXL underperformed the Australian Biotechs industry which returned 17.9% over the past year.

Return vs Market: HXL underperformed the Australian Market which returned 9.2% over the past year.

Price Volatility

Is HXL's price volatile compared to industry and market?
HXL volatility
HXL Average Weekly Movement20.8%
Biotechs Industry Average Movement10.8%
Market Average Movement8.4%
10% most volatile stocks in AU Market17.0%
10% least volatile stocks in AU Market3.3%

Stable Share Price: HXL's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine HXL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997n/aGeoffrey Kemplerhexima.com.au

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company’s lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.

Hexima Limited Fundamentals Summary

How do Hexima's earnings and revenue compare to its market cap?
HXL fundamental statistics
Market capAU$1.67m
Earnings (TTM)-AU$753.18k
Revenue (TTM)AU$193.86k

8.6x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HXL income statement (TTM)
RevenueAU$193.86k
Cost of RevenueAU$17.10k
Gross ProfitAU$176.76k
Other ExpensesAU$929.94k
Earnings-AU$753.18k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0045
Gross Margin91.18%
Net Profit Margin-388.53%
Debt/Equity Ratio0%

How did HXL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.